© 2018 Miraculo Inc. All Rights Reserved
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Cannabinoids are a collection of naturally occurring chemical compounds that are situated in the marijuana plant (cannabis sativa). Cannabidiol (CBD) is the main chemical within the cannabis plant and it is said by the wide scientific community that it has anti inflammatory effects when induced into animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said to have a psychotropic effect. Endogenous cannabinoid receptors (CB1 and CB2) are located in the endocannabinoid system and gives cannabinoids power to bind and thrive in the body. This study will evaluate the use of major cannabinoids in the treatment of parkinson’s disease. Parkinson’s Disease (PD) is a long-term neurodegenerative disorder of the central nervous system that mainly contributes to motor symptoms.
Cannabinoids may alleviate dyskinesia
The lateral segment of the globus pallidus (GPl) is said to be quite functional in levodopa-induced dyskinesia in PD. By triggering the cannabinoid receptors in the endocannabinoid system by selective therapeutic cannabinoids can enhance ‘GABA’ transmission and might be able to reduce the impacts of dyskinesia. In a randomized, double-blind, placebo-controlled, crossover study with 7 people, the scientists in this research were able to show that the syntetic cannabinoid receptor agonist nabilone massively decreases levodopa-induced dyskinesia in PD.
Endocannabinoid system may be a target for therapeutics for signs of parkinson’s disease
The endocannabinoid system has an important role in numerous physiological activities and has been discovered to be changed in different pathological syndromes, including slow movement disorders. The relationship between cannabinoids and dopamine in the basal ganglia are quite complex and include both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the triggering of different receptors, cannabinoid receptors 1 and 2. Despite current cannabinoid-based products have been suggested for motor and nonmotor effects of PD, so far, conclusions from clinical research are controversial and inconclusive. Further clinical research including larger samples of people, appropriate molecular sites, and particular clinical outcome measures are required to clarify the efficiency of cannabinoid-based therapies.